Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
Ravichandran S, Mahmood S, Wisniowski B, Sachchithanantham S, Popat R, Lachmann H, Rabin N, Ramasamy K, Hawkins S, Kyriakou C, Gillmore J, Yong K, Hawkins P, Jackson G, Pratt G, D Wechalekar A. Ravichandran S, et al. Among authors: popat r. Br J Haematol. 2022 Jul;198(2):328-332. doi: 10.1111/bjh.18216. Epub 2022 May 4. Br J Haematol. 2022. PMID: 35509237
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network. Popat R, et al. Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12. Lancet Haematol. 2016. PMID: 27843120 Free article. Clinical Trial.
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Maciocia N, Melville A, Cheesman S, Sharpley F, Ramasamy K, Streetly M, Jenner M, Benjamin R, Schey S, Maciocia P, Popat R, D'sa S, Rismani A, Cerner A, Yong K, Rabin N. Maciocia N, et al. Among authors: popat r. Br J Haematol. 2017 Mar;176(6):908-917. doi: 10.1111/bjh.14547. Epub 2017 Feb 17. Br J Haematol. 2017. PMID: 28211054 Free article.
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
Latifoltojar A, Hall-Craggs M, Bainbridge A, Rabin N, Popat R, Rismani A, D'Sa S, Dikaios N, Sokolska M, Antonelli M, Ourselin S, Yong K, Taylor SA, Halligan S, Punwani S. Latifoltojar A, et al. Among authors: popat r. Eur Radiol. 2017 Dec;27(12):5325-5336. doi: 10.1007/s00330-017-4907-8. Epub 2017 Jun 27. Eur Radiol. 2017. PMID: 28656463 Free PMC article.
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL. Chin M, et al. Among authors: popat r. Blood Cancer J. 2017 Sep 15;7(9):e610. doi: 10.1038/bcj.2017.76. Blood Cancer J. 2017. PMID: 29016571 Free PMC article. Clinical Trial. No abstract available.
203 results